Kenneth H. Cowan
#164,316
Most Influential Person Now
Kenneth H. Cowan's AcademicInfluence.com Rankings
Kenneth H. Cowanphilosophy Degrees
Philosophy
#9604
World Rank
#13190
Historical Rank
Logic
#6573
World Rank
#8102
Historical Rank
Kenneth H. Cowanbiology Degrees
Biology
#13217
World Rank
#16750
Historical Rank
Pathology
#195
World Rank
#325
Historical Rank
Download Badge
Philosophy Biology
Kenneth H. Cowan's Degrees
- Masters Medicine University of Nebraska Medical Center
- PhD Pathology University of Nebraska Medical Center
Why Is Kenneth H. Cowan Influential?
(Suggest an Edit or Addition)Kenneth H. Cowan's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. (1995) (870)
- Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. (1986) (762)
- The pharmacology and clinical use of methotrexate. (1983) (739)
- BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage (2002) (526)
- The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. (2002) (432)
- Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. (1989) (365)
- Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. (1997) (354)
- Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. (1987) (314)
- Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. (1986) (290)
- Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. (2000) (281)
- Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. (1994) (277)
- A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. (1994) (250)
- Glutathione S-transferases and drug resistance. (1990) (242)
- BRCA1 Effects on the Cell Cycle and the DNA Damage Response Are Linked to Altered Gene Expression* (2000) (232)
- Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. (1987) (222)
- Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. (1995) (211)
- A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells (1997) (198)
- Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. (1987) (196)
- Hormone-dependent regulation of BRCA1 in human breast cancer cells. (1995) (191)
- Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. (1995) (187)
- Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. (1983) (173)
- Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. (1996) (171)
- An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue. (1990) (171)
- Elevation of pi class glutathione S-transferase activity in human breast cancer cells by transfection of the GST pi gene and its effect on sensitivity to toxins. (1989) (169)
- A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. (1988) (146)
- Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. (1992) (144)
- Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells (1998) (141)
- Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. (1999) (139)
- Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. (1999) (136)
- Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. (2005) (135)
- A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. (1984) (135)
- Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. (1994) (132)
- Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. (1991) (131)
- Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. (1988) (123)
- A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. (1993) (122)
- Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. (1995) (115)
- Differences in phosphate metabolite levels in drug-sensitive and -resistant human breast cancer cell lines determined by 31P magnetic resonance spectroscopy. (1986) (111)
- Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. (1990) (111)
- Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. (1996) (108)
- Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. (1987) (107)
- Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. (1990) (107)
- Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. (1995) (103)
- Amplification of 4q21–q22 and the MXR gene in independently derived mitoxantrone‐resistant cell lines (2000) (99)
- Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. (1995) (99)
- Transforming Growth Factor-β1 Circulates in Normal Human Plasma and is Unchanged in Advanced Metastatic Breast Cancer (1995) (98)
- Identification of 5' and 3' sequences involved in the regulation of transcription of the human mdr1 gene in vivo. (1993) (96)
- Structure of the human genomic glutathione S-transferase-pi gene. (1989) (92)
- Mechanisms and clinical significance of multidrug resistance. (1988) (92)
- Irradiation-induced G2/M checkpoint response requires ERK1/2 activation (2007) (90)
- The effect of systemic therapy on local-regional control in locally advanced breast cancer. (1992) (89)
- Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation. (1995) (88)
- Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. (1995) (83)
- Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. (1994) (82)
- Intestinal folate transport: identification of a cDNA involved in folate transport and the functional expression and distribution of its mRNA. (1996) (80)
- Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer (1993) (79)
- Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. (1995) (78)
- Wild Type p53 Stimulates Expression from the Human Multidrug Resistance Promoter in a p53-negative Cell Line (*) (1995) (75)
- Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. (1996) (74)
- Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. (1991) (74)
- Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells. (1989) (74)
- Results of the National Cancer Institute early breast cancer trial. (1992) (73)
- Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. (2000) (72)
- Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. (1997) (71)
- BRCA1 signals ARF-dependent stabilization and coactivation of p53 (1999) (68)
- Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. (1982) (68)
- Reversible transcriptional activation of mdr1 by sodium butyrate treatment of human colon cancer cells. (1994) (66)
- Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates. (1993) (66)
- Breast cancer risk reduction. (2010) (66)
- Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/Waf1 expression in human breast epithelial cells. (1995) (66)
- Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. (1996) (66)
- Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. (1994) (65)
- Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: effect on cellular sensitivity to cytotoxic agents. (1992) (65)
- Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. (1992) (64)
- Structure and function of the 5'-flanking sequence of the human cytosolic selenium-dependent glutathione peroxidase gene (hgpx1). (1992) (63)
- Glutathione S-transferase and drug resistance. (1989) (62)
- BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation (2005) (60)
- Immunohistochemical expression of π‐class glutathione S‐transferase is down‐regulated in adenocarcinoma of the prostate (1997) (60)
- Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. (1997) (60)
- Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells (2007) (59)
- Multidrug resistance. (1990) (59)
- Inhibition of the growth of pre‐established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector (1997) (57)
- NCCN Clinical Practice Guidelines in Oncology for Breast Cancer Risk Reduction (2010) (57)
- Monoclonal antibodies to glutathione S‐Transferase π–immunohistochemical analysis of human tissues and cancers (1991) (56)
- BRCA1-induced Apoptosis Involves Inactivation of ERK1/2 Activities* (2002) (54)
- Drug Resistance and Its Clinical Circumvention (2003) (54)
- Protein phosphatase 2A has an essential role in the activation of γ-irradiation-induced G2/M checkpoint response (2010) (54)
- Adriamycin resistance in human tumor cells associated with marked alteration in the regulation of the hexose monophosphate shunt and its response to oxidant stress. (1987) (52)
- Regulation of human glutathione S-transferase pi gene transcription: influence of 5'-flanking sequences and trans-activating factors which recognize AP-1-binding sites. (1990) (52)
- Examination of human tumors for rhoA mutations. (1994) (51)
- Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. (2001) (51)
- Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. (1988) (49)
- RAC1 GTPase plays an important role in γ-irradiation induced G2/M checkpoint activation (2012) (48)
- Posttranscriptional control of glutathione S-transferase pi gene expression in human breast cancer cells. (1992) (48)
- Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines. (1989) (48)
- Heregulin-Dependent Delay in Mitotic Progression Requires HER4 and BRCA1 (2006) (46)
- Isolation, characterization, and expression in Escherichia coli of two murine Mu class glutathione S-transferase cDNAs homologous to the rat subunits 3 (Yb1) and 4 (Yb2). (1989) (45)
- Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells. (1992) (45)
- Reduced folate carrier gene (RFC1) expression and anti‐folate resistance in transfected and non‐selected cell lines (1997) (44)
- Breast cancer in young women: clinicopathologic correlation. (1999) (44)
- Brca1-Deficient Murine Mammary Epithelial Cells have Increased Sensitivity to CDDP and MMS (2004) (44)
- Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. (1993) (39)
- New aspects of clinical drug resistance: the role of gene amplification and the reversal of resistance in drug refractory cancer. (1986) (38)
- Breast cancer risk reduction, version 2.2015 clinical practice guidelines in oncology clinical practice guidelines in oncology (2015) (38)
- Neural stem cells in the adult ciliary epithelium express GFAP and are regulated by Wnt signaling. (2006) (38)
- Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. (1986) (38)
- Ca2+/Mg(2+)-dependent endonuclease activation is an early event in VP-16-induced apoptosis of human breast cancer MCF7 cells in vitro. (1995) (36)
- Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells. (1995) (35)
- The phenomenon of pleiotropic drug resistance. (1987) (34)
- The Combination of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL/Apo2L) and Genistein Is Effective in Inhibiting Pancreatic Cancer Growth (2004) (33)
- Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer (1998) (33)
- Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter (2000) (33)
- The Multidrug Resistance‐associated Protein Gene Confers Drug Resistance in Human Gastric and Colon Cancers (1996) (33)
- A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation (2014) (33)
- Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein (2000) (32)
- Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial (2003) (32)
- Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. (1994) (32)
- Isolation and characterization of genomic sequences involved in the regulation of the human reduced folate carrier gene (RFC1). (1999) (32)
- Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity. (2005) (31)
- ERK1/2 Signaling Plays an Important Role in Topoisomerase II Poison-Induced G2/M Checkpoint Activation (2012) (31)
- Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. (1996) (31)
- Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin. (2002) (31)
- Tamoxifen and fenretinide in women with metastatic breast cancer (1999) (31)
- Markedly Decreased Expression of Glutathione S-Transferase π Gene in Human Cancer Cell Lines Resistant to Buthionine Sulfoximine, an Inhibitor of Cellular Glutathione Synthesis (*) (1995) (30)
- Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation (2014) (30)
- Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. (1996) (30)
- Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer. (1993) (30)
- Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-O renal cell carcinoma cells and regresses tumor growth of 786-O cells in nude mouse. (2004) (29)
- Detection of circulating tumor cells and micrometastases in Stage II, III, and IV breast cancer patients utilizing cytology and immunocytochemistry (2000) (28)
- A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. (1997) (28)
- Expression of wild-type p53 during the cell cycle in normal human mammary epithelial cells. (1994) (28)
- Drug Resistance in Breast Cancer (1999) (28)
- Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. (1996) (27)
- Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases. (1995) (27)
- Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. (1993) (26)
- A novel adenoviral vector expressing human Fas/CD95/APO-1 enhances p53-mediated apoptosis (1999) (26)
- In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. (1999) (25)
- Can Unknown Predisposition in Familial Breast Cancer be Family‐Specific? (2013) (25)
- Effects of estrogen and tamoxifen on the regulation of dihydrofolate reductase gene expression in a human breast cancer cell line. (1985) (24)
- Is c-erb B-2 a predictor for recurrent disease in early stage breast cancer? (1994) (23)
- Gene Transfer into Hematopoietic Cells: Implications for Cancer Therapy (1994) (23)
- Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line. (1991) (22)
- 8-chloroadenosine 3',5'-monophosphate as a novel modulator of multidrug-resistance. (1993) (22)
- Gamma-irradiation-induced DNA damage checkpoint activation involves feedback regulation between extracellular signal-regulated kinase 1/2 and BRCA1. (2008) (22)
- BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. (2005) (22)
- Antineoplastic Drug Resistance and Breast Cancer (1993) (22)
- Regulation of dihydrofolate reductase in human breast cancer cells and in mutant hamster cells transfected with a human dihydrofolate reductase minigene. (1986) (21)
- Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression. (2004) (21)
- Keynote address: multidrug resistance: a pleiotropic response to cytotoxic drugs. (1991) (21)
- Family-specific, novel, deleterious germline variants provide a rich resource to identify genetic predispositions for BRCAx familial breast cancer (2014) (20)
- Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272). (1990) (19)
- Multicenter Breast Cancer Collaborative Registry (2011) (19)
- Exome Analysis Reveals Differentially Mutated Gene Signatures of Stage, Grade and Subtype in Breast Cancers (2015) (19)
- KSR1 Is Required for Cell Cycle Reinitiation Following DNA Damage* (2009) (19)
- Adenoviral expression of the cyclin-dependent kinase inhibitor p27Kip1: a strategy for breast cancer gene therapy. (1998) (19)
- Glutathione S-transferases and antineoplastic drug resistance (1989) (17)
- Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. (2008) (16)
- Breast Cancer Risk Reduction, Version 2.2015. (2015) (16)
- Utilization of multiple polyadenylation signals in the human RHOA protooncogene. (1994) (15)
- Glutathione transferase GST pi in breast tumors evaluated by three techniques. (1993) (15)
- Drug resistance and cancer. (1993) (15)
- Current status of paclitaxel in the treatment of breast cancer (2004) (14)
- Multidrug resistance associated with altered topoisomerase II activity--topoisomerases II as targets for rational drug design. (1990) (14)
- Breast Cancer Collaborative Registry informs understanding of factors predicting sleep quality (2018) (13)
- Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor: implications for tumor vaccination. (1998) (13)
- Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12) (2000) (13)
- Breast cancer risk reduction. (2010) (13)
- TESTOSTERONE 5α-REDUCTASE AND THE ACCUMULATION OF DIHYDROTESTOSTERONE IN BENIGN PROSTATIC HYPERPLASIA (1979) (12)
- Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant (ABMT) with neoR-transduced bone marrow and peripheral blood stem cells in patients with metastatic breast cancer. (1993) (12)
- Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology. (2007) (12)
- A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy (1995) (12)
- A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. (1995) (12)
- Gene amplification in drug resistance: of mice and men. (1984) (11)
- Increased glutathione S-transferase activity (GST) in drug treated human breast cancer cells (1985) (11)
- Genome instability in blood cells of a BRCA1+ breast cancer family (2014) (11)
- Steroid receptors in breast cancer. (1982) (11)
- Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5‐fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin‐3 (1994) (11)
- Selenium-dependent glutathione peroxidase expression is inversely related to estrogen receptor content of human breast cancer cells. (1991) (11)
- Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines (2009) (10)
- Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan. (1995) (10)
- 5' Nucleotide sequences influence serum-modulated expression of a human dihydrofolate reductase minigene (1986) (10)
- Upregulation of DF3, in association with ICAM-1 and MHC class II by IFN-gamma in short-term human mammary carcinoma cell cultures. (1996) (10)
- Adenovirus expressing p27KIP1 induces apoptosis against cholangiocarcinoma cells by triggering Fas ligand on the cell surface. (2003) (9)
- Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer (1993) (9)
- Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway. (1986) (9)
- A Pilot Study of Dose Intense Doxorubicin and Cyclophosphamide Followed by Infusional Paclitaxel in High-Risk Primary Breast Cancer (2003) (8)
- Phase I study of taxol plus doxorubicin plus granulocyte colony-stimulating factor (G-CSF) in patients with metastatic breast cancer (1993) (7)
- Early Suppressive Effects of Chemotherapy on Recovery of Bone Marrow Megakaryocyte Precursors: Possible Relationship to Platelet Recovery (1996) (7)
- Dose-intensive therapy for breast cancer. (1993) (6)
- Multidrug resistance. (1997) (6)
- Association ofSOD3 promoter DNA methylation with its down-regulation in breast carcinomas (2020) (6)
- Multiple drug resistance in cancer therapy (1994) (5)
- Spontaneous Metastasis and Enhances Survival Mammary Tumors Inhibits Tumor Lymphangiogenesis and Factor-C Expression Using Small Interfering RNA Vectors in Down-Regulation of Vascular Endothelial Cell Growth (2005) (5)
- A pleiotropic response associated with resistance of breast cancer cells to antineoplastic drugs and hormonal agents. (1988) (5)
- Modulation of a human dihydrofolate reductase minigene following release from amino acid deprivation involves both 5' and 3' nucleotide sequences. (1988) (4)
- Expression of the GSTπ Gene and Response to Tamoxifen Therapy in Locally Advanced Breast Carcinomas a (1993) (4)
- RAC1 GTPase plays an important role in γ-irradiation induced G2/M checkpoint activation (2012) (4)
- Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature (2022) (3)
- Fazarabine: A Report of Response in a Patient with Multiply Relapsed Embryonal Cell Carcinoma (1993) (3)
- Genetic Variants in Circadian Rhythm Genes and Self-Reported Sleep Quality in Women with Breast Cancer (2019) (3)
- Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor. (1993) (3)
- Adriamycin resistance in MCF-7 cells expressing P-glycoprotein following transfection with protein kinase C alpha (1990) (3)
- Role of ABCG2 Transporter in Notch and CKIT-Mediated Maintenance of Retinal Stem Cells (2003) (2)
- Multidrug resistance. (1992) (2)
- Correction: Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation (2020) (2)
- Autologous dendritic cell vaccine directed at wild type p53 in patients with high-risk breast cancer treated with adjuvant chemotherapy. (2009) (2)
- 6 – Phosphoprotein and Protein Kinase C Changes in Human Multidrug-Resistant Cancer Cells (1988) (2)
- Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer (2015) (2)
- Multidrug resistance. (1999) (2)
- The Genome of Polymorphonuclear Neutrophils Maintains Normal Coding Sequences (2013) (1)
- CHANGES IN SKELETAL IMAGES INDUCED BY GRANULOCYTE- COLONY- STIMULATING FACTOR (G-CSF) (1996) (1)
- The impact of the affordable care act on breast cancer care in the USA: A multi‐institutional analysis (2019) (1)
- Multidrug resistance. (1994) (1)
- General Mechanisms of Drug Resistance (2003) (1)
- Receptor for Hyaluronan-Mediated Motility (RHAMM) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patients (2022) (1)
- Gene Therapy in Oncology (2020) (1)
- NCCN Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology (2010) (1)
- Potential Clinical Application of Strategies to Avert or Overcome Drug Resistance (2003) (1)
- CLASS GLUTATHIONE S-TRANSFERASE ACTIVATING IN HUMAN BREAST CANCER CELLS BY TRANSFECTION OF THE GST PGENE AND ITS EFFECT ON SENSIVITY TO TOXINS (1989) (1)
- Single‐base LOH can be used as Specific Marker to Classify BRCAx Familial Breast Cancer into More Homogenous Subtypes (2017) (1)
- Genome instability in blood cells of a BRCA1 + breast cancer family (2014) (1)
- Drug resistance markers: are they bad or good? (1997) (1)
- Multidrug resistance. (1988) (1)
- Multidrug resistance. (1991) (1)
- Structure and regulation of the human glutathione peroxidase gene (1990) (0)
- Phase I C linical T rial o f A litretinoin a nd T amoxifen i n Breast C ancer P atients: T oxicity, P harmacokinetic, a nd Biomarker E valuations (2001) (0)
- Resistance Factors Unique to Tumor Cells In Vivo: Host-Tumor-Drug Interactions (2003) (0)
- Response to "local control for locally advanced breast cancer: many opinions, few facts" (1992) (0)
- Multidrug resistance. (1996) (0)
- Drug resistance in medical and pediatric oncology (1987) (0)
- Combined modality (adjuvant) therapy in breast cancer (1982) (0)
- Breast Cancer Training Program for Summer Undergraduates (2002) (0)
- Identification of new susceptibility genes in familial breast cancer by exome sequencing. (2012) (0)
- ASO Visual Abstract: Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer (2022) (0)
- Chemosensitivity and DNA repair in BRCA1 deficient murine mammary epithelial cells (2005) (0)
- Twenty-five-Year Follow-up of a Prospective Randomized Trial Comparing Preoperative Versus Postoperative FLAC/Granulocyte Colony–Stimulating Factor Chemotherapy for Stage II Breast Cancer (2020) (0)
- Multidrug resistance. (1993) (0)
- Abstract 2041: Her2/Neu has an essential role for the gamma-irradiation-induced ERK1/2 signaling activation and G2/M checkpoint response (2012) (0)
- 185 – Biology of Cancer (2012) (0)
- Phase I and Pharmacokinetic Study of Arabinofuranosyl-5-azacytosine (Fazarabine, (2006) (0)
- Abstract #2485: ERK1/2 signaling plays an important role in the topoisomerase II inhibitor induced G2/M checkpoint response (2009) (0)
- Tumor and iatrogenic regulation of myeloid precursors and their potential to limit immune therapy. (2009) (0)
- Drug Resistance in Cancer (1989) (0)
- Mediated Uptake of Folate by a High-Affinity Binding Protein in Sublines of L 1210 Cells Adapted to Nonomolar Concentrations of Folate (2017) (0)
- Effects of Estrogen and Tamoxifen on the Regulation of Dihydrofolate ReducÃ-aseGene Expression in a Human Breast Cancer Cell Line (2006) (0)
- Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer (2022) (0)
- Family-specific, novel, deleterious germline variants provide a rich resource to identify genetic predispositions for BRCAx familial breast cancer (2014) (0)
- Breast Cancer Risk Reduction , Version 2 . 2015 Clinical Practice Guidelines in Oncology (2015) (0)
- Are Ciliary Epithelial Stem Cells Astrocytic in Nature (2003) (0)
- Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer. (2009) (0)
- Recent progress in breast cancer management. Combined modality (adjuvant) therapy. (1981) (0)
- Conclusion and Future Directions (2003) (0)
- Correction: KSR1 is required for cell cycle reinitiation following DNA damage. (2018) (0)
- Consequences of adenovirus-mediated p16 protein expression on cell cycle arrest are determined by the endogenous Rb status in human cancer cells (1997) (0)
- FUNCTIONAL P-GLYCOPROTEIN (PGP) AND WILD-TYPE (WT) P53 ACTIVITY ARE NOT ASSOCIATED WITH RESPONSE TO CHEMOTHERAPY IN CHILDHOOD ACUTE MYELOGENOUS LEUKEMIA (AML). 923 (1996) (0)
- Adriamycin-resistant Human Breast Cancer Cells Isolation of Amplified and Overexpressed DNA Sequences from (1987) (0)
- Breast Cancer Training Program (2005) (0)
- Withdrawal: BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. (2019) (0)
- Resistance to Multiple Drugs (2003) (0)
- Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy (2008) (0)
- A nonrandomized phase II study of dose-dense paclitaxel and cyclophosphamide (PC) in early-stage breast cancer (EBC). (2014) (0)
- Obesity and breast cancer: Analysis of Breast Cancer Collaborative Registry (BCCR) data in a rural community cancer center. (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kenneth H. Cowan?
Kenneth H. Cowan is affiliated with the following schools:
